Baromarin Pharmaceutical Inc. (BMRN) with a purchase classification

Biomarin Pharmaceutical Inc. (Nasdaq:BMRNFrom among 11 best genome stocks to buy according to hedge boxes. Gena Wang from Barclays maintained Biomarin Pharmaceutical Inc. (NASDAQ: BMRN) with a purchase rating with the price goal of $ 86.00 in a report published on June 10.

A pharmaceutical factory manufactures a form of the artificial oral c

According to the profit report at Biomarin Pharmaceutical Inc. (NASDAQ: BMRN) The company has achieved revenues of $ 745.15 million and 185.69 million dollars of net profit for the quarter that ended on March 31. The company’s sales amounted to 648.83 million dollars, and its net profit was 88.66 million dollars last year.

It is difficult to avoid previous comparisons with Genzyme (purchased by Sanofi) where Biomarin Pharmaceutical Inc. Although there are many adopted treatments, the company spent years in red due to its marketing and the costs of research and development, but analysts are optimistic about the long -term and profitable capabilities of its current wallet. It is in a strong position due to the wide inner pipeline and its ability to add expansion through strategic acquisitions.

While we acknowledge the BMRN capabilities as an investment, we believe that some artificial intelligence shares provide greater potential in the upward trend and carry less negative risks. If you are looking for a stock of artificial intelligence with less than very apprecia The best inventory of artificial intelligence in the short term.

Read the following: 10 high -growth shares EV to invest in them and 13 best car shares to buy in 2025.

Detection. no one.